If you typed TRIAL (Therapeutic Research Institute and Lab) into a search box, you are probably building a CRO or site shortlist for Guatemala. This article uses only what is public about TRIAL (trialresearch.org) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What TRIAL publishes
TRIAL describes itself as a CRO and site management organization (SMO) in Guatemala, offering regulatory services, investigational product management including storage and distribution, research site support and continuing education.
TRIAL vs bioaccess®
| Dimension | TRIAL | bioaccess® |
|---|---|---|
| Core focus | CRO/SMO, regulatory and logistics, Guatemala | First-in-human and early feasibility studies for medical devices |
| Geography | See provider site | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need a Guatemala-based CRO/SMO for regulatory, logistics and site support, TRIAL’s published services match.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including TRIAL, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
For the local regulatory path, see CRO in Guatemala. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.
Ready to compare a proposal? Request a first-in-human study proposal.
Facts from the TRIAL public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.